Unlock exclusive insights into the evolving T cell engager landscape
Track the latest developments in TCE research, trials, and therapeutic innovation.
What’s Inside:
- 1,000+ TCE assets tracked – with over 200 in active development
- Record number of Phase 2 trials in 2025 – autoimmune disorder indications gaining pace
- New targets & modalities – CD28, 4-1BB, and co-stimulatory trispecifics emerging
- $100B+ in deals since 2013 – find out which companies are still actively investing
- Global developer landscape – key activity hubs in the US, China, and across Europe
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
